Retrospective Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Oct 28, 2017; 23(40): 7283-7291
Published online Oct 28, 2017. doi: 10.3748/wjg.v23.i40.7283
Table 3 Patients with gastrointestinal neuroendocrine tumors: Selected measures n (%)
Development database
Validation database
CS CohortNon-CS CohortAllP valueCS CohortNon-CS CohortAllP value
n2517531004181543724
Abdominal pain166 (66.1)388 (51.5)554 (55.2)< 0.001104 (57.5)253 (46.6)357 (49.3)0.011
Dyslipidemia124 (49.4)347 (46.1)471 (46.9)0.36167 (37.0)209 (38.5)276 (38.1)0.724
Diverticulosis of colon68 (27.1)159 (21.1)227 (22.6)0.05037 (20.4)93 (17.1)130 (18.0)0.314
Liver disorder56 (22.3)79 (10.5)135 (13.4)< 0.00150 (27.6)44 (8.1)94 (13.0)< 0.001
Enlarged lymph nodes36 (14.3)40 (5.3)76 (7.6)< 0.00123 (12.7)25 (4.6)48 (6.6)< 0.001
Type 2 diabetes32 (12.7)158 (21.0)190 (18.9)0.00430 (16.6)91 (16.8)121 (16.7)0.954
Abdominal mass26 (10.4)35 (4.6)61 (6.1)0.01023 (12.7)16 (2.9)39 (5.4)< 0.001
Dyspepsia and other specified disorders of function of stomach26 (10.4)26 (3.5)52 (5.2)< 0.0018 (4.4)35 (6.4)43 (5.9)0.318